Acumen Pharmaceuticals, Inc.
ABOSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 25, 2024 | Citigroup | David Hoang | $7.00(+105%) | $3.41 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| BTIG | maintain | Buy | Nov 2, 2026 |
| Citigroup | downgrade | Buy →Neutral | Oct 30, 2026 |
| BTIG | maintain | Buy | Sep 16, 2026 |
| Citigroup | maintain | Buy | Sep 15, 2026 |
| BTIG | maintain | Buy | Mar 26, 2026 |
| BTIG | maintain | Buy | Mar 16, 2026 |
| BTIG | maintain | Buy | Jan 27, 2026 |
| B of A Securities | maintain | Buy | Nov 18, 2025 |
| B of A Securities | maintain | Buy | Aug 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 28, 2025 |
| UBS | maintain | Buy | Mar 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 3, 2024 |
| UBS | maintain | Buy | Aug 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2024 |
| UBS | maintain | Buy | Mar 31, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 27, 2024 |
| Credit Suisse | maintain | Outperform | Aug 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 9, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jul 17, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Jul 17, 2023 |
| Cantor Fitzgerald | maintain | Overweight | May 18, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 28, 2023 |
| Credit Suisse | maintain | Outperform | Mar 28, 2023 |
Earnings History
Next report: Mar 25, 2027 · EPS est. $-0.37| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 26, 2026 | $-0.35 | $-0.39 | — | — |
| Aug 11, 2026 | $-0.45 | $-0.36 | — | — |
| May 12, 2026 | $-0.33 | $-0.40 | — | — |
| Mar 26, 2026 | $-0.41 | $-0.50 | — | — |
| Nov 12, 2025 | $-0.44 | $-0.63 | — | — |
| Aug 12, 2025 | $-0.68 | $-0.54 | — | — |
| May 13, 2025 | $-0.48 | $-0.56 | — | — |
| Mar 27, 2025 | $-0.62 | $-0.47 | — | — |
News
Phase II ALTITUDE-AD trial top-line results are expected in November 2026. Cash reserves of $79 million will support operations into early 2027.
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS) at 18 months compared to placebo at either dose; key secondary endpoints, including CDR-SB, also did not achieve statistical significance -- -- Acumen to cease clinical development of sabirnetug, preserve cash and explore strategic options --
Acumen Pharmaceuticals is rated a speculative Buy ahead of November 2026 Phase 2 ALTITUDE-AD data for sabirnetug in early Alzheimer's disease. I estimate ABOS fair value at $2.57 per share, a 14% premium to market, based on risk-adjusted NPV and anticipated financing needs. Key upside hinges on sabirnetug achieving ≥30% iADRS slowing with manageable ARIA risk; subpar efficacy or safety would negate the thesis.
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals NASDAQ: ABOS said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble amyloid-beta oligomers in patients with Alzheimer's disease.
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in November 2026 IND filing for the Enhanced Brain Delivery™ (EBD®) program lead clinical candidate targeted for mid-2027 Cash, cash equivalents and marketable securities of $78.6 million as of September 30, 2026, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00…
NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key poster presentations at the upcoming 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Boston. The presentations focus on Acumen's Phase 2 ALTITUDE-AD trial of sabirnetu…
NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financ…
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.
ADAR1 Capital Management LLC acquired a new position in shares of Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 2,111,334 shares of the company's stock, valued at approximately $5,637,000. ADAR1 Capital Management LLC
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.
NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2026 and provided a business update.